After a Few Hiccups, All Bets Are on CRISPR Again

A research technician works to clone DNA in a lab. A letter published in a scientific journal last year challenged the safety of promising gene-editing tool CRISPR, unnerving researchers and investors alike. Now, a smattering of recent studies have redeemed the technology by showing how CRISPR can more precisely target disease.